A Study to Evaluate Baricitinib in Adults with Severe or Very Severe Alopecia Areata
Official Title
A Multicenter, Randomized, Double-Blind, Placebo-Controlled, Operationally Seamless, Adaptive Phase 2/3 Study to Evaluate the Efficacy and Safety of Baricitinib in Adult Patients with Severe or Very Severe Alopecia Areata (JAHO)Purpose
The main reason for you to take part in this study is not to treat you for your condition but to help in answering the following research questions:
• Whether baricitinib is better than placebo in the treatment of patients with severe alopecia areata (AA)
• The safety of baricitinib and any side effects you may have when you take it.
Could this study be right for you?
- Are at least 18 years and ≤60 years for males (≤70 years of age for females) at
the time of informed consent
- Are able to read, understand, and give documented (electronic or paper
signature) informed consent
- Current AA episode of more than 6 months’ duration and hair loss
encompassing ≥50% of the scalp
- No spontaneous improvement over the past 6 months